BioSpace News Archive

CURCUGEN®, DolCas Biotech’s bioavailability-enhanced, water-dispersible curcuminoid complex, has received Self-Affirmed Generally Recognized As Safe status.

Clinical Trial Matching Collaboration Will Enhance Identification of Patients with Any Solid Tumor Harboring an NRG1 Gene Fusion Identified Using NeoGenomics’ Advanced Gene Fusion Panels

Brings 25 years of preclinical and clinical drug development experience to ReForm

Newron Pharmaceuticals S.p.A., a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, announced its financial results and operational highlights for the year ended December 31, 2020, and provided an outlook for 2021.

Moderna Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced that the first participants have been dosed in the Phase 2/3 study, called the KidCOVE study, of mRNA-1273, the Company’s vaccine candidate against COVID-19, in children ages 6 months to less than 12 years.

Lexaria Bioscience Corp. , a global innovator in drug delivery platforms, announces extensive progress in two of the four planned antiviral drug studies in its 2021 applied research and development (R&D) program.

Successful introductory product trials result in an agreement by three major hospital chains to use the my-Cam device

The Purdue University Spinout’s NOV004, the first-ever targeted bone anabolic agent, has shown promise in accelerating fracture healing

UVision360, Inc., an innovative FemTech company, announces today that the U.S. Food and Drug Administration (FDA) has accepted the Company’s submission for expanded reprocessing procedures for use with the LUMINELLE DTx Hysteroscopy System

Cybin to Present at the Oppenheimer 31 st Annual Healthcare Conference